James R. Taylor

James R. Taylor

Auto-generated profile, based on publicly available information

James R. Taylor

Medical School, University of Sheffield, Sheffield, South Yorkshire, UK

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2022 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
PDF file
JTJames Taylor
James Taylor
MSMichael Spiller
Michael Spiller
KRKara Ranguin
Kara Ranguin
AVAntonio Vitobello
Antonio Vitobello
CPChristophe Philippe
Christophe Philippe
Meena BalasubramanianMeena Balasubramanian
Meena Balasubramanian
Pathogenic variants in heterogeneous nuclear ribonucleoprotein U (HNRNPU) results in a novel neurodevelopmental disorder recently delineated. Here, we report on 17 previously unpublished patients carrying HNRNPU pathogenic variants. All patients were found to harbor de novo loss‐of‐function variants except for one individual where the inheritance could not be determined, as a parent was unavailable for testing. All patients had seizures which started in early childhood, global developmental delay, intellectual disability, and dysmorphic features. In addition, hypotonia, behavioral abnormalities (such as autistic features, aggression, anxiety, and obsessive–compulsive behaviors), and cardiac (septal defects) and/or brain abnormalities (ventriculomegaly and corpus callosum thinning/agenesis) were frequently observed. We have noted four recurrent variants in the literature (c.1089G>A p.(Trp363*), c.706_707del p.(Glu236Thrfs*6), c.847_857del p.(Phe283Serfs*5), and c.1681dels p.(Gln561Serfs*45)).

1 June 1998 in Injury
Verified
Journal Article
Closed access
JTJ.R. Taylor
J.R. Taylor
LTL.T. Twomey
L.T. Twomey
BKB.A. Kakulas
B.A. Kakulas

27 February 2019 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
JPJason Powell
Jason Powell
JTJames Taylor
James Taylor
SGScott G. Garland
Scott G. Garland
Objective: The purpose of this article is to review the available clinical trial data for andexanet alfa and its role in clinical practice. Data Sources: A MEDLINE/PubMed search was conducted (January 2000 to January 2019) using the keyword andexanet alfa for clinical trials. References of identified articles were searched by hand for additional citations. Study Selection and Data Extraction: We included English-language articles related to the Food and Drug Administration (FDA) approval of andexanet alfa or provided novel information regarding this drug entity. Data Synthesis: The findings of the review show that andexanet alfa may be a safe and effective option for the reversal of apixaban and rivaroxaban. Relevance to Patient Care and Clinical Practice: With the approval of this reversal agent, patients and providers can feel safer when using apixaban and rivaroxaban, which in turn may increase the use of these anticoagulant agents. Conclusions: The new FDA approval of andexanet alfa will allow safer use of oral anticoagulants and will likely further the use of direct oral anticoagulants for anticoagulant needs. Reversing enoxaparin-/edoxaban-induced bleeding with this agent should be limited because there is no FDA approval owing to the fact that only phase II trial data available.

1 November 1999 in Management Communication Quarterly
Verified
Journal Article
Closed access
JTJames R. Taylor
James R. Taylor

29 August 2020 in Clinical Therapeutics
Verified
Journal Article
Closed access
PDF file
JPJason Powell
Jason Powell
CPChris Piszczatoski
Chris Piszczatoski
JTJames R. Taylor
James R. Taylor